

THERAVECTYS FILES SUIT IN THE U.S. AGAINST IMMUNE DESIGN CORP.

PARIS, July 25, 2014

BUSINESS WIRE - THERAVECTYS announced that it filed a lawsuit against Seattle-based Immune Design Corp. (“IDC”) in the Delaware Court of Chancery and is seeking preliminary and permanent injunctive relief, as well as monetary damages. In its suit, THERAVECTYS raises claims of tortious interference with contractual relations, misappropriation of trade secrets, unfair competition and unjust enrichment.

Lawsuit raises claims of tortious interference with contractual relations,
misappropriation of trade secrets, unfair competition and unjust enrichment

The lawsuit alleges that IDC induced THERAVECTYS’ exclusive manufacturer, **Henogen SA** (“Henogen”), to **breach its exclusivity obligations** by manufacturing and supplying cGMP clinical batches of lentiviral vectors for IDC. As a result, **the lawsuit claims that IDC misappropriated THERAVECTYS’ trade secrets**, tortiously interfered with THERAVECTYS’ contractual relationship, has been unjustly enriched and is knowingly using lentiviral vectors unlawfully manufactured for IDC by Henogen. This **lawsuit follows an April 11, 2014 judgment in the Paris Commercial Court in THERAVECTYS’ favor**. In that judgment, the Paris Commercial Court found, among other things, that Henogen had breached its contractual obligations to THERAVECTYS by making lentiviral vectors for IDC.

The **lawsuit seeks monetary damages**, as well as injunctive relief preventing IDC from (1) directly or indirectly **using lentiviral vector vaccines developed or produced by Henogen**; and (2) citing to the U.S. Food and Drug Administration or otherwise relying **upon any clinical trials using lentiviral vector vaccines developed or produced by Henogen**.

About THERAVECTYS

THERAVECTYS is a Paris-based, privately owned, fully-integrated discovery & clinical development biotech company capitalizing **15 years of fundamental research at the Pasteur Institute** in the field of **lentiviral vectors** and from which the company has secured an **exclusive worldwide patent license agreement** for the use the lentiviral vectors in vaccination and immunotherapy applications.

Strongly supported by **renowned investors** and **former global pharmaceutical executives**, the company rapidly progresses in its R&D activities and in-house production capabilities. THERAVECTYS is determined to lead the

vaccination paradigm shift and offer to patients valuable & affordable treatments against cancer and major global infectious diseases for which the induction of a strong cellular immune response is required.

With **promising preliminary safety and immunogenicity results** from its **HIV vaccine candidate** currently in Phase I/II, THERAVECTYS is now accelerating the development of further vaccine candidates in several oncology and infectious disease indications with the aim to **bring to market innovative treatments** with current unmet need, alone or in collaboration with partners.

For more information:

+33 1 43 90 19 20 - contact@theravectys.com



THERAVECTYS - Villejuif BioPark, 1 Mail du Professeur Georges Mathé 94800 VILLEJUIF, FRANCE - SARL Capital: 147 356,20 EUR

www.theravectys.com